Playtex Sport continues support of Women’s Sports Foundation through donation, Facebook campaign
SHELTON, Conn. — Playtex has extended its partnership with the Women’s Sports Foundation.
Playtex said it is donating $150,000 to further the foundation’s mission of advancing the lives of girls and women through physical activity and sport via the brand’s Playtex Sport line. What’s more, the Playtex Sport brand is leveraging its own Facebook community to raise awareness of the foundation’s important mission and to inspire action by encouraging users to share and pledge their support. Additionally, visitors to the Facebook page also will find ways to improve their workout routines, download a Playtex Sport coupon, watch and share inspirational videos featuring active girls, as well as view personal messages from such Women’s Sports Foundation champion athletes as Angela Ruggiero (ice hockey), Jessica Mendoza (softball) and Leslie Osborne (soccer). The brand said the goal is to reach a pledge of 100,000.
"With the 40th Anniversary of Title IX and on the eve of the London Olympic Games, this is a year to reflect on and celebrate the heights that women have achieved through sport," Playtex Sport senior brand manager Chit Itchon said. "We’re proud to support the Women’s Sports Foundation for a second year. Its mission aligns to our own brand values that encourage the confidence, personal achievement and friendship that young women forge on and off the field. We hope that women everywhere will join us in pledging to Play On, each and every day."
Harris Teeter, Lowes Foods swap store locations
CHARLOTTE, N.C. — Two North Carolina-based grocery stores have announced a purchase and sale agreement.
Harris Teeter will acquire 10 of the Lowes Foods’ store locations in the central Carolinas region, while Lowes Foods will acquire six Harris Teeter store locations in western North Carolina. In addition to six of its stores being acquired by Lowes Foods, Harris Teeter said it also will pay the latter $26.5 million. The transaction is expected to be completed in the company’s third quarter of fiscal 2012, which ends July 1.
"This transaction aligns with our strategic plans to replace rural store locations with more urban locations with higher density of our target demographic groups," Harris Teeter board chairman and CEO Thomas Dickson said. "It provides us with the opportunity to explore in selected locations an innovative format that we think our customers will find exciting."
Human Genome Sciences rejects GSK’s bid
ROCKVILLE, Md. — One month after GlaxoSmithKline announced its tender offer to acquire Human Genome Sciences, HGS said Friday that its board of directors has rejected the unsolicited bid.
As previously reported, GSK in May said it commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13 per share in cash, a premium of 81% to HGS’s closing share price of $7.17 per share on April 18, the last trading day before HGS publicly disclosed GSK’s private offer. Since then, HGS had said the unsolicited offer was inadequate; however, the waiting period the Hart-Scott-Rodino Antitrust Improvement Act of 1976 had expired Friday, giving GSK the green light to acquire the drug maker.
"The HGS board of directors has rejected GSK’s unsolicited $13 per share offer, after concluding unanimously that the GSK offer is inadequate, does not reflect the value inherent in HGS and is not in the best interests of our stockholders," HGS said in a release. "We announced on April 19 that our board has authorized the exploration of strategic alternatives in the best interests of stockholders, including a potential sale of the Company. This process continues to be active and fully underway. We invited GSK to participate in this process, but GSK declined and instead commenced its unsolicited tender offer, which seeks to circumvent, disrupt and prematurely end our strategic review process to the disadvantage of HGS stockholders. We are committed to completing this process as expeditiously as possible. The HGS Board of Directors recommends that HGS stockholders reject GSK’s tender offer and not tender any of their shares to GSK."